Archives

Abstract Number: 931 – Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Presenter: Binod Dhakal, MBBSSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 2:45 PM–3:00 PMLocation: San Diego Ballroom AB...

Abstract Number: 923 – A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Presenter: Hua Jiang, PhDSession: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic MalignanciesDate & Time: Monday, December 9, 2024 3:45 PM–4:00 PMLocation: Hall B (San...

Abstract Number: 898 – Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Presenter: Elias K. Mai, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early RelapseDate & Time: Monday, December 9, 2024 3:30 PM–3:45 PMLocation: Pacific Ballroom Salons 24-26...

Abstract Number: 897 – Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Presenter: Danai Dima, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early RelapseDate & Time: Monday, December 9, 2024 3:15 PM–3:30 PMLocation: Pacific Ballroom Salons 24-26...

Abstract Number: 894 – Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis

Presenter: Moshe E Gatt, MDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL AmyloidosisDate & Time: Monday, December 9, 2024 4:00 PM–4:15 PMLocation: Pacific Ballroom...

« Older Entries

Next Entries »

Abstract Number: 931 – Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Abstract Number: 923 – A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Abstract Number: 898 – Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Abstract Number: 897 – Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Abstract Number: 894 – Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis

Recent Posts

Recent Comments

Categories

Meta